Improved ovarian adiponectin system expression in polycystic ovary syndrome treated with exenatide
- Author:
Asma VATANKHAH
1
;
Mohabbat JAMHIRI
;
Sima VATANKHAH
;
Keivan LORIAN
;
Mohammad Ebrahim REZVANI
;
Mahin IZADI
Author Information
- Publication Type:Brief Communication
- From:Clinical and Experimental Reproductive Medicine 2025;52(1):98-100
- CountryRepublic of Korea
- Language:English
- Abstract: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder that can cause infertility. This experimental study was conducted to elucidate the role of adiponectin signaling in rats with PCOS treated with exenatide. Twenty-eight adult female Wistar rats were divided into four groups of seven. The normal group did not receive any drug. The PCOS+vehicle (Veh) group received estradiol valerate to induce PCOS, then was divided into PCOS +E50 and PCOS+E100 groups and treated with 50 or 100 mg/kg doses of exenatide, respectively. The mRNA expression of adiponectin and adiponectin receptor 1 (Adipo-R1) was evaluated using a semi-quantitative real-time polymerase chain reaction. The results indicated that the level of adiponectin diminished in the PCOS rats while exenatide increased adiponectin expression at both doses. Adiponectin receptor mRNA levels were higher in the PCOS rats than in the normal rats (p<0.05). In addition, exenatide decreased the levels of Adipo-R1 expression. Taken together, our results showed that exenatide may improve PCOS characteristics in rats through the molecular regulation of adiponectin and its receptor.
